rituximab + cyclophosphamide + doxorubicin + vindesine + bleomycin + prednisone

R-ACVBP is an intensive immunochemotherapy regimen used as a first-line treatment for aggressive B-cell lymphomas, most notably diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBL). The regimen consists of the anti-CD20 monoclonal antibody rituximab combined with a chemotherapy backbone of doxorubicin (Adriamycin), cyclophosphamide, vindesine, bleomycin, and prednisone. Developed by the Groupe d'Etude des Lymphomes de l'Adulte (GELA), R-ACVBP is a dose-dense induction therapy typically followed by a sequential consolidation phase involving methotrexate, ifosfamide, and etoposide. Clinical trials, such as the LNH 03-2B study, have demonstrated that R-ACVBP provides superior event-free and overall survival compared to the standard R-CHOP regimen in younger patients with low-intermediate risk profiles, although it is associated with a higher profile of hematologic toxicity.

Other names

R-ACVBP regimen